Although pembrolizumab provided the greatest clinical benefit in QALYs for patients with PD-L1 CPS ≥ 10, the cost of PFS state was less in the esophageal squamous cell carcinoma due to the shorter PFS compared with the PD-L1 CPS ≥ 10. Here, CD274 is linked to esophageal squamous cell carcinoma.